Boston, MA (PRWEB) April 1, 2010
Dr. Thomas A. Einhorn, internationally renowned Orthopaedic Surgeon and Chairman of the Department of Orthopaedic Surgery and Professor of Orthopaedic Surgery, Biochemistry and Biomedical Engineering at Boston University, is safely reversing early avascular necrosis (AVN) of the hip in patients aged 20 to 60 with his innovative Bone Marrow Aspirate Concentration (BMAC) treatment utilizing Adult Stem Cells. Harvesting non-embryonic stem cells from one’s own bone marrow, Dr. Einhorn has for the past two years successfully reduced, and in many cases eliminated, AVN using the direct inoculation of autologous bone marrow stem cells, a method that reduces the risk of rejection. This safe alternative to the more invasive hip replacement, practiced safely by only a select few surgeons nationwide, grows new bone for restoration of function and pathology of hip joints. “The idea is that once the stem cells are in the cavity, they will induce the development of new blood vessels and start to grow, differentiating into bone tissue,” says Dr. Einhorn. “This new bone tissue should then use the surrounding necrosed tissue as a scaffold, putting living bone back where it belongs.” After the procedure, patients can bear full weight after a week, and resume exertional physical activity at six months.
Dr. Einhorn believes “A total hip replacement is often a sub-optimal solution for patients under 60 years of age due to possible activity restrictions and the fact that a synthetic hip joint will wear out with time. Stem cell therapy could prevent some patients from requiring this operation.”
Einhorn’s Groundbreaking Stem Cell Treatment Substantiated by Clinical Protocol and Extensive Research
With numerous unsubstantiated claims pertaining to stem cell cures for conditions that include cardiac failure, multiple sclerosis, osteoarthritis, neurological disorders, tissue regeneration, and muscle damage, Dr. Einhorn advises patients to be cautious when selecting stem cell treatments, as many have not been proven safe or effective. As Einhorn reported at the March 2010 American Academy of Orthopaedic Surgeon’s Annual Meeting, “In the last decade, there has been a lot of excitement with the development of new procedures and technologies. It is critical now to push the envelope on research to determine if these new technologies are effective.”
To support his high success rate with BMAC stem cell treatments, Dr. Einhorn is conducting a four-year prospective case series study, initiated in December, 2009, which has been approved by his Institutional Review Board. Its purpose is to assess the relationship between clinical results in the patient and several indices of stem cell vitality that include the number and distribution of specific types of stem cells, the ability of those cells to grow in cell culture in the laboratory, the ability of stem cells to make tissue that can calcify like bone, and the ability of cells to induce the formation of blood vessels, as blood vessels enhance healing. In addition, Dr. Einhorn will quantitate the patient’s functional and systemic recovery, and release preliminary results at periodicintervals at national and international medical society congresses.
Dr. Einhorn's research at the Boston University Orthopaedic Research Lab has been funded by the National Institutes of Health since 1990. Working closely with a team of 50 physicians and scientists, including orthopaedic surgeons, Ph.D. scientists, graduate students, orthopaedic doctors in training, nurse practitioners, and post doctorate fellows, Dr. Einhorn continues to research and develop new therapies to enhance the repair of bone, and the blood supply to bone.
Stem Cell Therapy could eventually eliminate the need for joint replacement,” says Dr. Einhorn. Rather than surgically replacing joints, as has been the standard medical approach in the past, therapies of the future will focus on the use of stem cells and gene therapy in the new scientific field of tissue re-engineering. "It's the future of our specialty," adds Dr. Einhorn.
“In July of 2008 I traveled from Texas to Boston for a BMAC procedure with Dr. Einhorn. Over the previous two years I had undergone multiple surgeries for Avascular Necrosis in both hips and the right knee. While the surgeries helped for awhile, they were not a solution, and I had no choice but to use a wheelchair.Through my research, I learned about Dr. Einhorn and the BMAC procedure, which used my own stem cells injected into a core decompression to generate new bone. I emailed Dr. Einhorn and within minutes I had a reply and was speaking to his assistant. I was overjoyed to make contact with a doctor that was so sincerely willing to listen to my case.In It has been a little over a year since my stem cell procedure performed by Dr. Einhorn. I arrived in Boston using a wheelchair and crutches. Today I am able to kick a soccer ball with my 8 year old son. I am able to run around the park with him and ride bikes together. I am able to hold hands with my husband on evening walks. Being in a wheelchair did not stop me from living, but now I live life on my terms- and on my own two feet. Dr. Einhorn and his entire team were tantamount to my recovery.” Cindy Preece, Dallas, Texas
Thomas A. Einhorn, M.D., is Chairman of the Department of Orthopaedic Surgery, and Professor of Orthopaedic Surgery, Biochemistry and Biomedical Engineering at Boston University. Since 1982, Einhorn has been regarded as a leading surgeon specializing in reconstructive surgery of the hip and knee in Boston and New York. Internationally acclaimed as an authority in the field of regenerative medicine, an area heralded as the future of orthopaedics, Dr. Thomas A. Einhorn has been consistently recognized in Castle Connolly's America's Top Doctors, Best Doctors, Best Doctors of Boston, and Best Doctors of New York.
A dedicated expert in revolutionary Adult Stem Cell Treatments for Orthopaedic conditions, Dr. Thomas A. Einhorn is available for in-person and telephone Interviews.